A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2013 |
| End Date: | January 2015 |
| Contact: | Mitchell L Shiffman, MD |
| Email: | mitchell_shiffman@bshsi.org |
| Phone: | 804-977-8920 |
A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir
1. A maximally tolerated dose of ribavirin can be defined in each patient with ESRD
undergoing hemodialysis.
2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease
(ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with
peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.
3. A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis
can achieve rapid virologic response (RVR), extended virologic response (eRVR) and
sustained virologic response (SVR) when treated with peginterferon alfa-2b, the
maximally tolerated dose of ribavirin and boceprevir.
undergoing hemodialysis.
2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease
(ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with
peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.
3. A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis
can achieve rapid virologic response (RVR), extended virologic response (eRVR) and
sustained virologic response (SVR) when treated with peginterferon alfa-2b, the
maximally tolerated dose of ribavirin and boceprevir.
Patients with ESRD will be treated with a dose escalation of ribavirin starting from 200 mg
everyday (QD) to a maximal tolerated dose. Peginterferon will then be added. Ribavirin will
be dose adjusted as needed. Boceprevir will then be added. Ribavirin will be dose adjusted
as needed. Patients will be monitored for eRVR and SVR. The study end-point is eRVR.
everyday (QD) to a maximal tolerated dose. Peginterferon will then be added. Ribavirin will
be dose adjusted as needed. Boceprevir will then be added. Ribavirin will be dose adjusted
as needed. Patients will be monitored for eRVR and SVR. The study end-point is eRVR.
Inclusion Criteria:
- Chronic HCV defined by:
- A history of a positive anti-HCV or HCV RNA for > 6 months or
- A liver biopsy demonstrating at least portal fibrosis
- HCV genotype 1
- No prior treatment with any interferon or peginterferon preparation
- ESRD undergoing hemodialysis for at least 6 months
- Willingness not to conceive a child during treatment and for 6 months following
discontinuation of treatment.
Exclusion Criteria:
- Histologic evidence of cirrhosis
- Any co-existent liver disease
- A platelet count < 90,000
- A total white blood cell (WBC) < 2.5
- An absolute neutrophil count < 1.5
- Hemoglobin < 11 gm/dl on Epoetin-alpha
- Positive test for anti-HIV
- Pregnancy of the patient or their intimate partner
- Women who are breast feeding
- Significant cardiovascular disease
- History of suicide intent, severe depression requiring hospitalization or significant
psychiatric disease
- Malignancy within 5 years of enrollment except for squamous or basal cell skin cancer
- Co-existent immune disorder such as lupus, rheumatoid as arthritis, colitis, Crohns
disease, sarcoidosis, etc.
- Any patient in the opinion of the investigator who would not be a satisfactory study
candidate
We found this trial at
1
site
Click here to add this to my saved trials
